Clozapine is the prototypical atypical antipsychotic with multi-receptor antagonism including dopamine D4 and serotonin receptors, reserved for treatment-resistant schizophrenia due to risk of agranulocytosis requiring mandatory haematological monitoring. Simson Pharma's Clozapine reference standard and impurities support the stringent stability-indicating QC this closely monitored medication requires.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Clozapine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.